Acalabrutinib-Venetoclax Combos Improve QOL, Safety by Age in CLL

Fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, produced earlier and more durable improvements in quality of life (QOL) than did chemoimmunotherapy (CIT) in treatment-naive chronic lymphocytic leukemia (CLL), and the regimens' safety profile held up across age groups, according to research presented at the European Hematology Association (EHA) 2026 Congress.^1,2

Both analyses draw on the phase 3 AMPLIFY trial (NCT03836261), which previously showed that fixed-duration acalabrutinib-venetoclax (AV) and acalabrutinib-venetoclax-obinutuzumab (AVO) significantly prolonged progression-free survival (PFS) compared with CIT, leading to the FDA approval of AV as the first all-oral, time-limited frontline regimen for CLL.³ The new data add patient-reported outcome and age-stratified safety detail previously flagged as open questions for clinicians weighing regimen choice.⁴

How Did Quality of Life Differ Across Regimens?

Among 834 patients who received at least 1 dose of AV (n = 291), AVO (n = 284), or CIT (n = 259) in AMPLIFY, global health status/QOL and physical functioning improved from baseline across all 3 arms, but gains were larger and more sustained with AV and AVO.¹ The share of patients reporting a clinically meaningful QOL improvement, according to a 10-point or greater increase, rose from baseline to 1 year post treatment in 47.8% of the AV group and 43.5% of the AVO group vs 39.0% with CIT. Physical functioning followed a similar pattern, with improvement rates of 33.8% and 30.1% compared with 23.9%, respectively, at the same time point. Night sweats showed the earliest symptom relief, improving faster with AV and AVO than CIT, while fever remained uncommon across all arms.

What Do the Age-Stratified Safety Data Show?

Older patients (65 years and older) entered the AMPLIFY trial with reduced renal function and higher comorbidity scores, with the data presented at EHA reporting numerically higher rates of grade 3 or higher adverse events (AEs) and serious AEs (SAEs) in this group, particularly with AVO: SAEs occurred in 43.0% of older patients who received AVO vs 23.7% of younger patients who received AV.^1,2 Fatal SAEs followed the same pattern, rising to 11.6% among older patients who received AVO, largely COVID-19–related. These findings echo prior reporting that COVID-19 exposure during AMPLIFY’s 2019-2021 enrollment window complicated interpretation of its safety data.⁵

The poster also shows that leukopenia and neutropenia were more frequent with AVO than AV across both age groups and that thrombocytopenia and hepatotoxicity followed a similar pattern; major hemorrhage was numerically highest among older patients who received AVO.² It further breaks down discontinuations by individual drug rather than treatment overall, showing that COVID-19 remained the leading reason for stopping acalabrutinib, venetoclax, or obinutuzumab, with older patients discontinuing at higher rates across all 3. Dose withholding and dose reductions of acalabrutinib and venetoclax, too, were more common among patients 65 years and older, again mostly attributed to AEs.

Despite these differences, PFS benefits with AV and AVO over CIT were preserved in both age subgroups, with HRs ranging from 0.42 to 0.84 depending on arm and age group and mirroring results in the overall trial population.^1,2

Where Does This Leave Payers and Health Systems?

Together, this research reinforces the case that fixed-duration, chemotherapy-free regimens can offer both a tolerability and a patient-experience advantage over CIT, adding to prior coverage of AMPLIFY’s efficacy and cost implications for payers weighing time-limited vs continuous Bruton tyrosine kinase inhibitor strategies.⁶ Because the trial’s COVID-19 exposure occurred during a narrow pandemic window, plan sponsors and clinicians may want longer-term follow-up to confirm whether the age-related safety differences persist independent of that confounding. Additional QOL time points are also expected, which should further clarify the durability of the patient-reported benefits described in the companion analysis.¹

References

1. Kater AP, Brown JR, Ghia P, et al. Quality of life and symptoms with fixed-duration acalabrutinib + venetoclax ± obinutuzumab vs chemoimmunotherapy in treatment-naive chronic lymphocytic leukemia: patient-reported outcomes from AMPLIFY. Presented at: 2026 EHA Congress; June 11-14, 2026. Abstract PS1706.
2. Seymour JF, Aw A, Ribrag V, et al. Safety of fixed-duration (FD) acalabrutinib-venetoclax combinations in patients with chronic lymphocytic leukemia stratified by age: post hoc analysis of the phase 3 AMPLIFY trial. Poster presented at: 2026 EHA Congress; June 11-14, 2026. Abstract PF614.
3. Shaw ML. FDA approval of CLL combo marks new era for leukemia care. AJMC^®. February 20, 2026. Accessed July 22, 2026. https://www.ajmc.com/view/fda-approval-of-cll-combo-marks-new-era-for-leukemia-care
4. Shaw ML, Kittai AS. Fixed-duration AV is a compelling option, with important caveats: Adam Kittai, MD. AJMC. May 21, 2026. Accessed July 22, 2026. https://www.ajmc.com/view/fixed-duration-av-is-a-compelling-option-with-important-caveats-adam-kittai-md
5. Mattina C. COVID-19 death cloud interpretation of acalabrutinib-venetoclas combo results. AJMC. June 13, 2025. Accessed July 22, 2026. https://www.ajmc.com/view/covid-19-deaths-cloud-interpretation-of-acalabrutinib-venetoclax-combo-results
6. Caffrey M. Time-limited regimens gain notice, offering a break for patients with blood cancer and savings for payers. Evidence-Based Oncology. 2026;32(SP1):SP12.